Long intergenic non-protein coding RNA 2620 (LINC02620)

Long intergenic non-protein coding RNA 2620 (LINC02620), also known as Breast cancer-related transcript 1 (BCRT1), is a human long non-coding RNA (lncRNA) located on chromosome 10q25.1 and is approximately 1,013 nucleotides in length[1]. LINC02620 is non-coding, lacking protein-coding potential and a valid Kozak consensus sequence[1]. LINC02620 is significantly upregulated in breast cancer tissues compared with normal tissue and correlates with poor prognosis[1]. Functional studies show that BCRT1 promotes cell proliferation, survival, migration, invasion, and metastasis in multiple cancer types, including breast and cervical cancer[1][2][3]. Mechanistically, LINC02620 functions as a competing endogenous RNA (ceRNA), sponging microRNAs such as miR-1303 (in breast cancer) and miR-432-5p (in cervical cancer), which regulate targets like PTBP3 and CCR7, thereby promoting tumor progression[1][2]. BCRT1 is also implicated in modulating macrophage polarization (promoting the tumor-associated M2 phenotype) and mediating hypoxia-induced EMT in tumor cells[1]. Its overexpression is a potential prognostic biomarker and may represent a novel therapeutic target in breast and potentially other cancers[1][2][3]. No drugs are currently approved or known to target LINC02620 directly, and its targeting in therapy would need to address concerns related to its broad involvement in cancer cell biology.

Other names

BCRT1Breast cancer-related transcript 1LINC02620